What do systematic reviews say?

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

Summary of findings: Octreotide showed no clear difference in diarrhoea (grade 2+) compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.01 [0.76, 1.35]
  2 studies · 340 participants
  Moderate

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Probiotics vs placebo or control

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Probiotics vs placebo or control

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adverse events with anti‐gram‐positive antibiotics vs placebo

Mortality with anti‐gram‐positive antibiotics showed no clear difference in overall mortality compared with placebo (moderate certainty).

• Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer 2017 · Cochrane Headline outcomes only
  RR 0.9 [0.64, 1.25]
  8 studies · 1242 participants
  Moderate

Treatment failure with anti‐gram‐positive antibiotics vs placebo

Treatment failure with anti‐gram‐positive antibiotics showed no clear difference in overall failure (disregarding modifications) compared with placebo (low certainty).

• Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer 2017 · Cochrane Headline outcomes only
  RR 1 [0.79, 1.27]
  7 studies · 943 participants
  Low

Treatment failure with anti‐gram‐positive antibiotics vs placebo

It is very uncertain whether treatment failure with anti‐gram‐positive antibiotics changes failure, modifications included compared with placebo (very low certainty).

• Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer 2017 · Cochrane Headline outcomes only
  RR 0.72 [0.65, 0.79]
  11 studies · 2169 participants
  Very low

Adverse events with anti‐gram‐positive antibiotics vs placebo

It is very uncertain whether adverse events with anti‐gram‐positive antibiotics changes any adverse events compared with placebo (very low certainty).

• Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer 2017 · Cochrane Headline outcomes only
  RR 1.74 [1.5, 2.01]
  9 studies · 1936 participants
  Very low

Oral analgesia vs placebo

• Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 129 participants
  Very low

Imiquimod vs placebo

Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ overall response compared with placebo (high certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 11.95 [3.21, 44.51]
  3 studies · 104 participants
  High

Imiquimod vs placebo

Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ complete response compared with placebo (high certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 14.4 [2.97, 69.8]
  3 studies · 104 participants
  High
• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 18.24 [1.12, 296.41]
  1 study · 47 participants
  Moderate

Imiquimod vs placebo

Summary of findings for imiquimod probably leads to higher response to treatment at 12 months ‐ overall response compared with placebo (moderate certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 9.1 [2.38, 34.77]
  1 study · 47 participants
  Moderate

Imiquimod vs placebo

Summary of findings for imiquimod showed no clear difference in progression to vulval cancer at 12 months compared with placebo (low certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 0.48 [0.05, 4.93]
  1 study · 47 participants
  Low

Imiquimod vs placebo

Summary of findings for imiquimod leads to lower HPV DNA persistence compared with placebo (high certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 0.43 [0.26, 0.72]
  1 study · 47 participants
  High

Imiquimod vs placebo

Summary of findings for imiquimod leads to higher pain ‐ any grade compared with placebo (high certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 3.43 [1.8, 6.52]
  1 study · 52 participants
  High

Imiquimod vs placebo

Summary of findings for imiquimod leads to higher dose reductions compared with placebo (high certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 7.77 [1.61, 37.36]
  2 studies · 83 participants
  High

Imiquimod vs placebo

The review found no eligible studies for this question.

• Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Imiquimod vs placebo

The review found no eligible studies for this question.

• Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found